GRAIL, Inc. Selling and Marketing Expense
GRAIL, Inc. (GRAL) reported Selling and Marketing Expense of $37.66 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2026-08-06
- GRAIL, Inc. selling and marketing expense for the quarter ending 2026-06-30 was $37.66M, a 31.95% increase year-over-year.
- GRAIL, Inc. selling and marketing expense for the quarter ending 2026-03-31 was $30.67M, a 12.32% decline year-over-year.
- GRAIL, Inc. selling and marketing expense for the quarter ending 2025-12-31 was $27.67M, a 9.35% decline year-over-year.
- GRAIL, Inc. selling and marketing expense for the quarter ending 2025-09-30 was $25.50M, a 28.41% decline year-over-year.
- GRAIL, Inc. selling and marketing expense for fiscal 2025 was $116.69M, a 24.20% decline from fiscal 2024.
- GRAIL, Inc. selling and marketing expense for fiscal 2024 was $153.96M, a 5.14% decline from fiscal 2023.
- GRAIL, Inc. selling and marketing expense for fiscal 2023 was $162.29M, a 32.67% increase from fiscal 2023.
- GRAIL, Inc. selling and marketing expense for fiscal 2023 was $122.33M.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 6 month | Selling and Marketing Expense 9 month | Selling and Marketing Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $37.66M 10-Q · filed 2026-08-06 | $68.33M 10-Q · filed 2026-08-06 | $96.00M derived: sum of 3 quarters · filed 2026-08-06 | $121.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $30.67M 10-Q · filed 2026-05-07 | $58.34M derived: sum of 2 quarters · filed 2026-05-07 | $83.84M derived: sum of 3 quarters · filed 2026-05-07 | $112.38M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $27.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $53.17M derived: sum of 2 quarters · filed 2026-03-12 | $81.71M derived: sum of 3 quarters · filed 2026-08-06 | $116.69M 10-K · filed 2026-03-12 |
| 2025-09-30 | $25.50M 10-Q · filed 2025-11-13 | $54.04M derived: sum of 2 quarters · filed 2026-08-06 | $89.02M 10-Q · filed 2025-11-13 | $119.55M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $28.54M 10-Q · filed 2026-08-06 | $63.52M 10-Q · filed 2026-08-06 | $94.04M derived: sum of 3 quarters · filed 2026-08-06 | $129.67M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $34.98M 10-Q · filed 2026-05-07 | $65.50M derived: sum of 2 quarters · filed 2026-05-07 | $101.13M derived: sum of 3 quarters · filed 2026-05-07 | $142.12M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $30.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $66.15M derived: sum of 2 quarters · filed 2026-03-12 | $107.14M derived: sum of 3 quarters · filed 2026-03-12 | $153.96M 10-K · filed 2026-03-12 |
| 2024-09-30 | $35.63M 10-Q · filed 2025-11-13 | $76.61M derived: sum of 2 quarters · filed 2025-11-13 | $123.43M 10-Q · filed 2025-11-13 | $162.56M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-06-30 | $40.99M 10-Q · filed 2025-08-13 | $87.81M 10-Q · filed 2025-08-13 | $126.93M derived: sum of 3 quarters · filed 2026-03-12 | $163.53M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-03-31 | $46.82M 10-Q · filed 2025-05-14 | $85.94M derived: sum of 2 quarters · filed 2026-03-12 | $122.54M derived: sum of 3 quarters · filed 2026-03-12 | $163.28M derived: sum of 4 quarters · filed 2026-03-12 |
| 2023-12-31 | $39.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $75.72M derived: sum of 2 quarters · filed 2026-03-12 | $116.46M derived: sum of 3 quarters · filed 2026-03-12 | $162.29M 10-K · filed 2025-03-05 |
| 2023-10-01 | $36.60M 10-Q · filed 2024-11-13 | $77.33M derived: sum of 2 quarters · filed 2024-11-13 | $123.17M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $40.74M 10-Q · filed 2024-08-13 | $86.57M 10-Q · filed 2024-08-13 | ||
| 2023-01-01 | $122.33M 10-K · filed 2025-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Caris Life Sciences, Inc. (CAI) | United States | $9.119B | 47.87 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |